要查看或添加评论，请登录
david geliebter的更多文章
-
Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA? in Treating Large Hemispheric Infarction, Including Wake-Up Strokes2025年3月18日
Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA? in Treating Large Hemispheric Infarction, Including Wake-Up Strokes
NEW YORK, March 18, 2025 – Remedy Pharmaceuticals, a leader in stroke drug development, today announced that the U.S.
6
-
Woolsey Pharmaceuticals Completes B Round Extension To Advance Its ALS Program2025年2月27日
Woolsey Pharmaceuticals Completes B Round Extension To Advance Its ALS Program
NEW YORK – February 27, 2025, Woolsey Pharmaceuticals today announced the successful completion of an extension to its…
6
1 条评论 -
International Stroke Conference 2025: Remedy Pharmaceuticals Unveils Landmark CIRARA? Data Demonstrating Significant Improvements in Stroke Outcomes2025年2月18日
International Stroke Conference 2025: Remedy Pharmaceuticals Unveils Landmark CIRARA? Data Demonstrating Significant Improvements in Stroke Outcomes
NEW YORK, February 18, 2025 – Remedy Pharmaceuticals, a leader in stroke drug development today announced efficacy data…
13
2 条评论 -
Remedy Pharmaceuticals to Showcase Groundbreaking Phase 3 CHARM Study Data on CIRARA? at International Stroke Conference 20252025年1月29日
Remedy Pharmaceuticals to Showcase Groundbreaking Phase 3 CHARM Study Data on CIRARA? at International Stroke Conference 2025
NEW YORK, January 29, 2025 – Remedy Pharmaceuticals, the developer of CIRARA (intravenous glyburide) for the treatment…
1
-
Woolsey Pharmaceuticals Secures Additional Key U.S. Patent Claims for BRAVYL? (oral fasudil) in Treating ALS, Including Reducing Neurofilament Light2025年1月10日
Woolsey Pharmaceuticals Secures Additional Key U.S. Patent Claims for BRAVYL? (oral fasudil) in Treating ALS, Including Reducing Neurofilament Light
NEW YORK, January 10, 2025 – Woolsey Pharmaceuticals, whose mission is to usher in a new era of neurodegenerative…
10
-
Woolsey Reveals Breakthrough Findings Showing Spread of Toxic TDP-43 Pathology Greatly Reduced in BRAVYL? (oral fasudil) Treated ALS Patients2024年12月9日
Woolsey Reveals Breakthrough Findings Showing Spread of Toxic TDP-43 Pathology Greatly Reduced in BRAVYL? (oral fasudil) Treated ALS Patients
New York – December 9, 2024 – Woolsey Pharmaceuticals, a clinical-stage pharmaceutical company developing BRAVYL (oral…
2
-
Martin Pharmaceuticals Secures Exclusive Rights From Mitsubishi Tanabe Pharma for Docarpamine to Treat Decompensated Chronic Liver Disease Including A2024年12月3日
Martin Pharmaceuticals Secures Exclusive Rights From Mitsubishi Tanabe Pharma for Docarpamine to Treat Decompensated Chronic Liver Disease Including A
NEW YORK, NY – December 3, 2024 Martin Pharmaceuticals, a clinical-stage pharmaceutical company developing CIQUAAX?…
2
-
Remedy Pharmaceuticals Receives FDA Guidance to Advance CIRARA for Treatment of Severe Stroke2024年11月19日
Remedy Pharmaceuticals Receives FDA Guidance to Advance CIRARA for Treatment of Severe Stroke
NEW YORK, November 19, 2024 – Remedy Pharmaceuticals, a leader in stroke drug development, announced today that a Type…
9
-
Woolsey Pharmaceuticals Completes Patient Recruitment for High-Dose Cohort of ALS Study2024年11月12日
Woolsey Pharmaceuticals Completes Patient Recruitment for High-Dose Cohort of ALS Study
NEW YORK – November 12, 2024, Woolsey Pharmaceuticals today announced the successful completion of patient recruitment…
4